160 related articles for article (PubMed ID: 36606533)
1. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Buckstein R; Chodirker L; Yee KWL; Geddes M; Leitch HA; Christou G; Banerji V; Leber B; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Parmentier A; Thambipillai A; Tang D; Westcott C; Cameron C; Spin P
Leuk Lymphoma; 2023 Mar; 64(3):651-661. PubMed ID: 36606533
[TBL] [Abstract][Full Text] [Related]
2. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
Jouzier C; Cherait A; Cony-Makhoul P; Hamel JF; Veloso M; Thepot S; Cluzeau T; Stamatoullas A; Garnier A; Guerci-Bresler A; Dimicoli-Salazar S; Pica GM; Cheze S; Santana C; Chermat F; Fenaux P; Park S
Transfusion; 2022 May; 62(5):961-973. PubMed ID: 35452143
[TBL] [Abstract][Full Text] [Related]
3. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Buckstein R; Chodirker L; Mozessohn L; Yee KWL; Geddes M; Zhu N; Shamy A; Leitch HA; Christou G; Banerji V; Brian L; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Delage R; Parmentier A; Thambipillai A; Siddiqui M; Westcott C; Cameron C; Mamedov A; Spin P; Tang D
Leuk Lymphoma; 2022 Dec; 63(13):3165-3174. PubMed ID: 36095125
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
5. Red blood cell transfusion in myelodysplastic syndromes: A systematic review.
Kaka S; Jahangirnia A; Beauregard N; Davis A; Tinmouth A; Chin-Yee N
Transfus Med; 2022 Feb; 32(1):3-23. PubMed ID: 34927286
[TBL] [Abstract][Full Text] [Related]
6. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Jabbour E; Kantarjian HM; Koller C; Taher A
Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
[TBL] [Abstract][Full Text] [Related]
7. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
8. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
9. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
10. Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights.
Finelli C; Parisi S; Paolini S
Expert Rev Hematol; 2022 May; 15(5):411-421. PubMed ID: 35549626
[TBL] [Abstract][Full Text] [Related]
11. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
12. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
[TBL] [Abstract][Full Text] [Related]
13. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
[TBL] [Abstract][Full Text] [Related]
14. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
[TBL] [Abstract][Full Text] [Related]
15. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
Balducci L
Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
[TBL] [Abstract][Full Text] [Related]
16. Physicians' experience in blood supply shortages and the top factors that impact the clinical, economic, and humanistic outcomes of patients with myelodysplastic syndromes in 5 European countries.
Gupta S; Kulasekararaj AG; Costantino H; Grisolano J; Tang J; Jones S; Tang D
Curr Med Res Opin; 2023 Feb; 39(2):239-247. PubMed ID: 36453466
[TBL] [Abstract][Full Text] [Related]
17. Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Santini V; Giagounidis A; Pelligra CG; Franco-Villalobos C; Tang D; Morison J; Beach CL; Hu A; Platzbecker U; Fenaux P
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e874-e883. PubMed ID: 35710702
[TBL] [Abstract][Full Text] [Related]
18. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.
Zeidan AM; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Podoltsev NA; Gore SD; Ma X; Davidoff AJ
Leuk Lymphoma; 2019 Dec; 60(13):3181-3187. PubMed ID: 31170846
[TBL] [Abstract][Full Text] [Related]
19. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
20. Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates.
Durairaj S; Chew S; Hyslop A; Keenan N; Groves MJ; Tauro S
Am J Hematol; 2011 May; 86(5):406-10. PubMed ID: 21523799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]